Human IL13 Recombinant Protein (HEK293 Expression) — Tag Free
Price range: $850.00 through $6,300.00
HEK293 × Chaperone-Assisted Technology
Produced using our proprietary Z-Active® platform — HEK293 mammalian expression with chaperone-assisted folding for proper disulfide bonding, N-linked glycosylation, and 5–10× higher bioactivity vs Leading Suppliers.
Overview
Interleukin-13 (IL-13) is a monomeric 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergy, cancer, and tissue fibrosis. It is secreted by several helper T cell subsets, NK cells, mast cells, eosinophils, basophils, and visceral smooth muscle cells (1‑3). Mature human IL-13 shares approximately 58% amino acid sequence identity with mouse and rat IL-13. Despite the low homology, it exhibits cross‑species activity between human, mouse, and rat (4). IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances by macrophages, fibroblasts, and endothelial cells. On B cells, it promotes cellular activation, immunoglobulin class switching to IgE, and the up‑regulation of CD23/Fc epsilon RII (1, 5). IL-13 binds with low affinity to the transmembrane IL-13 R alpha 1 which then forms a signaling complex with the transmembrane IL-4 R alpha (6‑8). This high affinity receptor complex also functions as the type 2 IL-4 receptor (6, 7). IL‑13 R alpha 2 inhibits responses to both IL-13 and IL-4. It binds IL-13 with high affinity (9, 10) and prevents IL-13 from signaling through the IL-13 R alpha 1/IL-4 R alpha complex (11, 12). It also blocks signaling through IL-4-occupied IL-13 R alpha 1/IL-4 R alpha receptor complexes (12, 13). In addition, IL-13-bound IL-13 R alpha 2 can directly promote tumor cell invasiveness and the development of tissue fibrosis (14‑16).
Specifications
- Species: human
- Expression System: HEK293
- Sequence: Leu25-Asn146
- Tag: Tag Free
- Molecular Weight: 13.3 KDa
- Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
- Endotoxin: < 1 EU/μg of the protein by LAL method.
- UniProt/Swiss-Prot: P35225
- Available Sizes: 10 µg, 50 µg, 1 mg
Bioactivity
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.5-2.5 ng/mL.
Formulation & Reconstitution
Formulation: 0.22 μm filtered solution of PBS, pH 7.4.
Reconstitution: 0.2 mg/mL in sterile PBS, pH7.4
Storage & Stability
Aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.
Quality Assurance
Each lot is tested for purity (SDS-PAGE, SEC-HPLC), endotoxin levels (LAL method), and bioactivity. A Certificate of Analysis (COA) is provided with every order.
Safety Data Sheets & Documentation
Protocols & Support
Reconstitution Protocol
1. Briefly centrifuge the vial to collect lyophilized powder at the bottom.
2. Reconstitute in sterile deionized water or PBS to a concentration of 0.2–1.0 mg/mL.
3. Gently pipette up and down to dissolve. Do not vortex.
4. Aliquot and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.
Download Data Sheet
Complete product data sheet including batch-specific QC data, sequence information, and storage guidelines.
Download PDF Data Sheet
